Clodronate as a cause of aminotransferase elevation

Osteoporosis International

Volumn 10, Issue 2, 1999, Pages 120-122

  Laitinen, Kalevi ^a   Taube, T ^a  

^a Oy Leiras Finland Ab   (Finland)

Author keywords

Adverse events; Aminotransferases; Bisphosphonates; Clodronate; Liver enzymes

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLODRONIC ACID; LIVER ENZYME;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GASTROINTESTINAL SYMPTOM; GOOD CLINICAL PRACTICE; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOPENIA; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ALANINE TRANSAMINASE; ANALGESICS, NON-NARCOTIC; ANALYSIS OF VARIANCE; ASPARTATE AMINOTRANSFERASES; BONE DISEASES, METABOLIC; CLODRONIC ACID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PROSPECTIVE STUDIES;

EID: 0032882767     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980050205     Document Type: Article

References (13)

1. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42:919-44.
2. Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient, 2nd ed. London: Parthenon Publishing Group, 1995.
3. Plosker GL, Goa KL. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994;47:945-82.
4. Bounameaux HM, Sheifferli J, Montani J-P, Jung A, Chatelanat F. Renal failure associated with intravenous bisphosphonates. Lancet 1983;I:471.
5. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Safety 1996;14:158-70.
6. Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxy propylidene)-1,1-bisphosphonate. Br J Cancer 1988;58:621-5.
7. Leyvraz S, Hess U, Flesch G, Bauer J, Hauffe S, Ford JM. Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 1992;84:788-92.
8. Rosen HN, Moses AC, Gundberg C, Kung VT, Seyedin SM, Chen T. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J Clin Endocrinol Metab 1993;77:664-9.
9. Conte PF, Latreille L, Mauriac F, et al. Delay of progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996;14:2552-9.
10. Nussbaum SR, Warrell RP Jr, Rude R, et al. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 1993;11:1618-23.
11. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodelling. Am J Med 1995;99:144-52.
12. Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997;75:602-5.
13. Fukumoto S, Matsumoto T, Takebe K, Onaya T, Eto S, Nawata H. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients. J Clin Endocrinol Metab 1996;79:165-70.